Linagliptin is the generic name of the active ingredient found in medications like Trajenta. As mentioned earlier, it is a medication used to treat type 2 diabetes. Linagliptin belongs to the dipeptidyl peptidase/4 (DPP/4) inhibitor class of drugs. DPP/4 inhibitors work by inhibiting the action of the DPP/4 enzyme, which breaks down incretin hormones. Incretins are hormones released by the intestine in response to food intake. They help stimulate insulin release from the pancreas and reduce the amount of glucose produced by the liver, ultimately helping to lower blood sugar levels. By inhibiting DPP/4, linagliptin increases the activity of these incretin hormones, which leads to improved blood sugar control in people with type 2 diabetes. Linagliptin is taken orally in the form of a tablet and is typically prescribed as part of a comprehensive treatment plan for type 2 diabetes, which may include lifestyle changes, dietary adjustments, exercise, and other medications.